Cohort studyindependent cross-checkabstract checked I-BAR-139 standard review
US study: bowel inflammation after surgery
The Impact of Metabolic Bariatric Surgery on Inflammatory Bowel Disease Risk and Outcomes in Adults With Obesity: a Propensity-matched, Nationwide, Analysis.
Overview
Pusateri et al.. Obes Surg 2026 · PMID 42082785 · DOI 10.1007/s11695-026-08714-1
Bowel inflammation was less common in the first 3 years after surgery but more common afterwards, especially after sleeve; it remained rare.
Does the study support the specific claim? Partly · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
IBD timing after MBS
- How was the study done?
Claims cohort
- How many people, animals or samples were studied?
477,687
- What was actually found?
Late aHR 2.28
- How large was the observed effect?
61 vs 44 per 100,000/y
- What do the results mean in everyday life?
Small possible risk
- What are the study's limitations?
Claims data
- What does it say about Elawady's specific claim?
Partly supports IBD part
- Do the results apply to Germany and Europe?
US
- What can explicitly not be concluded from this study?
Causation
Scientific in-depth review
1. Full reference
- Authors
- Pusateri et al.
- Journal
- Obes Surg
- Year
- 2026
- Identifier
- PMID 42082785 DOI 10.1007/s11695-026-08714-1
- Verification
- verified – PubMed efetch 2026-10-26 + Crossref API
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
COI statement (PubMed record): Declarations. Ethical Considerations: The MarketScan Research Databases meet the criteria for a limited-use data set and contain none of the data elements prohibited by Health Insurance Portability and Accountability Act of 1996 (HIPAA), thus data is considered deidentified and this project was exempt from Institutional Review Board oversight. The disclosure list was shortened here; the complete statement is in the original publication.
2. Research question
What is the timing and severity of de novo IBD after MBS compared with obese controls?
3. Study design and population
- Study design
- Cohort study – Propensity-matched cohort in a US claims database (MarketScan)
- Population
Adults with severe obesity with or without RYGB/VSG
- Country
USA
- Period
not stated in abstract
- Sample size
100,832 MBS vs 376,855 controls
- Inclusion and exclusion criteria
Propensity-matched
4. Methods and endpoints
- Exposure / intervention
RYGB or VSG
- Comparator
Severe obesity without MBS
- Endpoints
UC or Crohn's <3 or >=3 y; severity proxies
- Statistical methods
Adjusted Cox
5. Actual results
- Results
IBD incidence 61.2 vs 44.4 per 100,000/year. Within 3 y: aHR 0.76 (0.60-0.95) (lower risk); VSG lower CD risk aHR 0.46. After 3 y: aHR 2.28 (1.02-5.06), particularly VSG. Higher colectomy proportion among UC patients after MBS (8.70% vs 1.57%, small numbers).
- Absolute risks
IBD incidence about 61 vs 44 per 100,000 per year.
- Authors' conclusion
MBS may lower IBD risk initially, but risk increases after 3 years, especially UC after VSG; findings on severity need caution.
6. Strengths
- Obese comparator
- Large
7. Weaknesses
- Claims data
- Late-period estimate imprecise (CI 1.02-5.06)
- Abstract only
8. Risk of bias
- Orienting tool
- ROBINS-E
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Claims coding; time-split analyses can be fragile.
9. Assessment of the statistical interpretation
Absolute excess ~17 per 100,000 per year; late HR imprecise.
10. Relevance to the specific claim
Strengthens the IBD signal after sleeve with an obese comparator, though absolute risk is very small and early risk was lower.
11. Independent contrary findings
Early lower risk; imprecise late estimate.
12. Transferability to Germany and Europe
US data.
13. Overall methodological judgement
Mixed signal for one immune-mediated disease; not evidence for autoimmune disease in general.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | low |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | mixed |
| Regional transferability | moderate |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Replication; mechanism.
15. Linked fact checks
- Sleeve gastrectomy causes autoimmune diseases and fibromyalgia. – Studies with mixed or unclear results